Using natriuretic peptides to 'guide' therapy in heart failure


Journal Article

Assays for B-type natriuretic peptide (BNP) and its cleavage equivalent amino terminal proB-type natriuretic peptide (NT-proBNP) have quickly progressed from being biochemical novelties to representing valuable diagnostic tools for the physician confronted with patients suffering from suspected or proven heart failure. Besides being useful adjuncts for the diagnostic evaluation of heart failure, these biomarkers have shown to be superior predictors of prognosis in patients so affected. An intriguing synergy between BNP and NT-proBNP with respect to therapy response has been observed, which has led to the intriguing concept of their use to unlock a personalised, optimal strategy for heart failure management. In this paper, we aim to review the current available data on natriuretic peptide guided therapy and provide some insights on the implementation of this approach in clinical practice. © TOUCH BRIEFINGS 2012.

Full Text

Duke Authors

Cited Authors

  • van Kimmenade, RRJ; Januzzi, JL

Published Date

  • January 1, 2012

Published In

Volume / Issue

  • 8 / 1

Start / End Page

  • 36 - 39

Electronic International Standard Serial Number (EISSN)

  • 1758-3764

International Standard Serial Number (ISSN)

  • 1758-3756

Digital Object Identifier (DOI)

  • 10.15420/ecr.2012.8.1.36

Citation Source

  • Scopus